Nuvectis Pharma's $140 Million Reboot: A Chinese Data Package Bets It Can Buy a US Franchise
A tiny oncology name buys two late-stage assets, swaps its lead program, and asks the FDA to believe the data
NVCT · Earnings Call · 2026-11-04
Nuvectis Pharma: The $140 Million Reboot
From oncology minnow to complement contender
Nuvectis Pharma's third quarter was not an incremental update; it was a corporate reset. The company used its first-ever earnings call tied to quarterly results to announce a licensing deal with China's Haisco for ex-China rights to two late-stage assets: NXP 100, an oral Factor B inhibitor already approved in China for PNH, and NXP 200, a brain-penetrant BRAF inhibitor. The old lead, NXP 900, is now a legacy combination program. Management did not hide the ambition: “The third quarter was transformational for Nuvectis... We have transformed Nuvectis into a late stage development company with the addition of 2 exciting drug candidates with best in class potential through our licensing agreement for ex China rights with our new partner, Haisco.” — Ron Bentsur, Executive · 2026-11-04 The balance sheet backs the rhetoric. Nuvectis raised $150 million in a follow-on and roughly $37 million through its ATM, ending the quarter with about $140 million in cash and a runway into the second half of 2029. Before that raise, the fundamentals told a tighter story: cash runway stood at 4.9 quarters at the last reported period end, with liabilities at 59.4% of assets, up more than 20 points year over year. That is what changed: not just a new pipeline, but the money to prosecute it.NXP-100: PNH, and the bigger nephrology swing
The core of the call was Factor B inhibition. NXP-100, also called ciprocfeltin, is a once-daily oral complement factor B inhibitor. In China it holds a first approval in newly diagnosed PNH based on a head-to-head Phase III win versus SOLIRIS, and a second marketing application in previously treated PNH is under review, with Haisco expected to announce approval in the first quarter of 2027. The commercial logic is straightforward: PNH is roughly a $5 billion market today, historically dominated by injectable C5 inhibitors, and Novartis's FABALTA has shown an oral factor B approach can scale — management said it is already running at about a $1 billion annualized rate roughly two years after launch. Nuvectis argues NXP-100 has a convenience edge (once daily versus twice daily) and possibly better pharmacodynamics, since Haisco engineered it as a half-life-optimized analog of the same mechanism. The IgA nephropathy opportunity may be the bigger swing, and it is not a lonely thesis: Vertex flagged IgA nephropathy as a live pipeline area in its own recent call. A 24-week Phase II for NXP-100 showed a 57% reduction in proteinuria and an almost 3-point eGFR increase versus a 1.5-point decline on placebo. “when you look at the Phase II data, especially at the key components, which are the proteinuria reduction of 57%, just pretty unprecedented. And also the eGFR increase of almost 3 points...” — Ron Bentsur, Executive · 2026-11-04 A fully powered 370-patient Phase III is running in China. If the eGFR benefit holds, NXP-100 could compete with the injectable APRIL/BAFF class on efficacy while winning on route of administration — and management's own framing is that oral factor B drugs become the backbone of any combination regimen, because nobody combines two injectables.NXP-200: the sleeper
The second asset is smaller today but may be the more interesting call option. NXP-200 is a paradox breaker BRAF inhibitor designed to avoid the paradoxical MAPK activation that limits first-generation drugs. In China it has breakthrough designation in BRAF V600 mutant high-grade glioma. At ESMO, Haisco reported a 40% objective response rate in high-grade glioma and 42.9% in low-grade glioma, including complete responses, with responses also seen in patients previously exposed to a BRAF inhibitor. Management argues the RANO 2.0 assessment makes the comparison to a rival second-generation BRAF look better than headlines suggest; that is their interpretation of another company's disclosure, and should be treated as such. Ron Bentsur was blunt: “I think that is a complete sleeper. I do not think anyone's paying any attention to it.” — Ron Bentsur, Executive · 2026-11-04 The near-term catalyst is a US IND by year-end, a US Phase Ib in early 2027, and updated solid tumor data from China — colorectal, melanoma, non-small cell lung and papillary thyroid — in early 2027. The Servier/Day One deal at $2.5 billion for a first-generation BRAF with roughly $225-250 million of projected sales is the benchmark management is quietly pointing at.The FDA asterisk
The central tension is that nearly all the clinical evidence was generated in China by Haisco. Nuvectis owns ex-China rights, but the US path is undefined — and the company's entire valuation hinge sits on that gap. Management said the first formal FDA interaction was in late September and that the agency is engaged. The range of outcomes is wide.That is the honest framing: the base case is a US trial, not a free pass. The company is hiring (a head of complement program poached from AstraZeneca), preparing KOL relationships and sites, and planning at least one IND by year-end. The planned migration of manufacturing to a Western CMO is another tell — management is hedging political risk, not just clinical risk.there are bookends to the possibilities here... one possibility is they will ask for 2 clinical trials... The other end of the spectrum is that they are going to require no studies... realistically, we believe that we are going to have to run a study.